Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
Recruiting
Observational Study
Lung Cancer (Diagnosis)
Nodule, Solitary Pulmonary
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,800 (estimated)
- Sponsor
- Herlev and Gentofte Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit
* Having signed informed consent
Exclusion Criteria:
* Active cancer, excluding non-melanoma skin cancer
* Comorbidities that exclude the patient from clinical follow-up and final dia…
Contacts